首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma
【2h】

The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma

机译:基质金属蛋白酶7和组织金属蛋白酶2抑制剂在透明细胞肾细胞癌中的表达及其临床意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Renal cell carcinoma (RCC) is one of the most common malignant neoplasms in the urinary system, and has a high frequency of local invasion and distant metastasis. This study assessed the expression and clinical significance of matrix metalloproteinase 7 (MMP-7) and tissue inhibitor of matrix metalloproteinases 2 (TIMP-2) in human clear cell renal cell carcinoma (CCRCC) by tissue microarray, immunohistochemistry and RT-PCR analysis. The expression of MMP-7 in CCRCC tissues was significantly higher compared with that in the control group (CG) and TIMP-2 expression in CCRCC, by contrast, was lower compared with that in the CG. The expression of MMP-7 and TIMP-2 in the CCRCC tissues was significantly correlated with the pathological grade and clinical stage. Log-rank analyses indicated that upregulation of MMP-7 and downregulation of TIMP-2 expression may occur during the progression of CCRCC, and Cox multivariate survival rate analysis demonstrated that there was also a positive correlation between the pathological grade, clinical stage, MMP-7 expression and survival rate. Thus, MMP-7 is an independent prognostic factor and MMP-7 and TIMP-2 may serve as useful molecular markers for evaluating prognosis in CCRCC patients.
机译:肾细胞癌(RCC)是泌尿系统中最常见的恶性肿瘤之一,局部浸润和远处转移的频率很高。本研究通过组织芯片,​​免疫组织化学和RT-PCR分析评估了基质金属蛋白酶7(MMP-7)和基质金属蛋白酶2组织抑制剂(TIMP-2)在人透明细胞肾细胞癌(CCRCC)中的表达及其临床意义。 CCRCC组织中MMP-7的表达明显高于对照组(CG),而CCRCC中TIMP-2的表达低于CG。 CCRCC组织中MMP-7和TIMP-2的表达与病理分级和临床分期密切相关。对数秩分析表明,在CCRCC进展过程中可能发生MMP-7上调和TIMP-2表达下调,Cox多变量生存率分析表明,病理分级,临床分期,MMP- 7表达和生存率。因此,MMP-7是一个独立的预后因素,MMP-7和TIMP-2可以作为评估CCRCC患者预后的有用分子标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号